Debt has become a substantial burden for developing countries due to limited access to financing, rising borrowing costs, currency devaluations and sluggish growth. These factors compromise the ...

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored ...

The deal, pending regulatory approvals, would give Ripple access to large enterprise clients as it is building out financial ...

Create a MotoGP™ account now and gain access to exclusive content, such as the MotoGP™ Newsletter, which features GP Reports, incredible videos and other interesting information about our sport.

Fintel reports that on October 15, 2025, Baird upgraded their outlook for Vor Biopharma (NasdaqGS:VOR) from Neutral to ...

Investing.com - 贝尔德 (Baird)周二将 Vor Biopharma, Inc. (NASDAQ:VOR) 的评级从"中性"上调至"优于大市"，同时大幅提高其目标价，从20.00美元上调至64.00美元。根据 InvestingPro 数据，该股票在过去六个月内已上涨超过120%，目前基于全面的公允价值分析显示其被低估。

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) stock gained 3.8% in premarket trading Tuesday after its collaborator RemeGen reported positive 48-week results from a Phase 3 study of telitacicept in ...

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) 股价在周二盘前交易中上涨3.8%，此前其合作伙伴荣昌生物 (RemeGen)报告了telitacicept在原发性干燥综合征三期研究中的48周积极结果。

Shares of Vor Bio (Nasdaq: NASDAQ:VOR) rose after it reported that its partner, RemeGen (OTCPK:REGMF), met the main goal in a ...

美军费近万亿，为何士兵军饷成问题？美军130万名现役军人，军饷怎么领？